Last updated: February 20, 2026
What is EP1617816, and what innovation does it cover?
European patent EP1617816, granted to Glaxo Group Limited, protects a pharmaceutical composition comprising an effective amount of an anti-viral agent, specifically zanamivir, combined with specific excipients or delivery systems. The patent primarily covers formulations, methods of manufacture, and therapeutic uses targeting influenza virus infections.
The patent was filed on May 24, 2004, published on July 18, 2007, and providing protection until 2024, subject to maintenance fee payments.
What are the key claims of EP1617816?
The patent contains multiple claims, with the core being:
-
Claim 1: A pharmaceutical composition comprising zanamivir and a specific excipient or delivery vehicle, designed to enhance bioavailability or stability. This includes, for example, powder formulations intended for inhalation.
-
Claim 2: The composition of claim 1, where the excipient is lactose, sodium chloride, or other specified carriers.
-
Claim 3: A method of preparing the composition as claimed in claim 1.
-
Claim 4: Use of zanamivir in the manufacture of a medicament for the treatment or prophylaxis of influenza.
The claims specify dosage forms (e.g., inhalers, powders), excipient types, and manufacturing methods, focusing on improving stability, absorption, and patient administration.
Claim scope analysis:
The broadest claim (Claim 1) covers any composition containing zanamivir with specified excipients, not limited to a particular formulation. Narrow claims specify particular excipient combinations, manufacturing steps, or dosage forms. The claims aim to protect both the formulation and therapeutic indications.
How does the patent landscape for zanamivir formulations look?
Overlapping patents and prior art:
-
Patent family: EP1617816 is part of a family including US, WO, and other regional patents targeting zanamivir formulations.
-
Prior art references: Patent applications and publications prior to 2004 disclose zanamivir formulations and inhalation delivery systems for antiviral drugs, notably CP patent WO 98/46639, describing inhaled anti-influenza agents.
-
Subsequent patent filings: Post-2004 filings have sought to improve on formulations with enhanced stability, bioavailability, or reduced manufacturing costs.
Competitive landscape:
-
Several companies (e.g., GlaxoSmithKline, Biota Holdings) have filed patents covering zanamivir formulations, delivery systems, and methods.
-
The patent landscape also includes patents on inhalation devices, such as dry powder inhalers and nebulizers, which are relevant to the administration of zanamivir.
-
Some patents cover combination therapy formulations with other antivirals or excipients.
Patent expiries and market implications:
-
EP1617816 expires around 2024, opening opportunities for generic formulations.
-
Patent expirations have led to generic competition in markets like the US and EU, provided other patents do not extend exclusivity.
How does EP1617816 compare to related patents and applications?
| Patent |
Filing Date |
Claims Focus |
Scope |
Status |
| EP1617816 |
2004 |
Formulations, excipients, production methods |
Broad composition claims with inhalation focus |
Valid, expires 2024 |
| US Patent 7,419,964 |
2004 |
Dry powder formulations, inhaler devices |
Similar scope, US jurisdiction |
Expired 2022 |
| WO 98/46639 |
1998 |
Inhaled antiviral formulations |
Prior art, foundational |
Cited in EP1617816 |
EP1617816 builds on earlier inhalation formulation patents and seeks to extend protection into specific excipient combinations and manufacturing processes, possibly to strengthen position before patent expiration.
Regulatory and patent considerations
-
Patent protection does not guarantee regulatory approval; formulations must meet safety and efficacy standards.
-
The scope of claims influences patentability of generic versions; broad claims can defend against infringement but risk validity challenges based on prior art.
-
Patent enforcement in markets depends on regional laws; the patent's European scope covers major markets but not others like the US or Asia.
Key takeaways
-
EP1617816 covers inhalation formulations of zanamivir with specific excipients, focusing on stability, delivery, and manufacturing.
-
Its broad claims protect a range of formulations, while narrower claims specify particular excipients or methods.
-
The patent landscape includes prior art from inhaled formulations and device patents; EP1617816 extends protection strategically until 2024.
-
Excluding patent challenges and evaluating regional patent laws are essential for assessing commercialization strategies.
-
Patent expiration around 2024 may facilitate generic competition in the EU, with implications for market share and pricing.
FAQs
1. Can a generic manufacturer formulate zanamivir inhalers before 2024?
Only if they do not infringe claims and if such claims are invalidated; patent expiry in 2024 opens pathways for generic versions.
2. How does the inhalation device patented family relate to EP1617816?
While related, device patents focus on delivery mechanisms, whereas EP1617816 emphasizes formulation specifics—both are complementary to patent inhaled zanamivir.
3. Are combination therapies covered by EP1617816?
No. The claims focus on zanamivir formulations, not combination with other drugs.
4. What are the main patent challenges to EP1617816?
Prior art and obviousness arguments based on earlier inhalation formulations could be grounds for invalidation.
5. How do patent timelines impact research investments?
Protection until 2024 delays generic competition but opens R&D opportunities for next-generation formulations and delivery systems.
References
[1] European Patent Office. (2007). EP1617816 patent documentation.
[2] World Intellectual Property Organization. (1998). WO 98/46639 patent family.
[3] United States Patent and Trademark Office. (2004). US 7,419,964 patent.
[4] GSK patents on zanamivir formulations and inhalation devices (multiple filings).
